Based on this clear evidence of clinical benefit, T-DM1 is now the standard treatment for patients with HER2-positive breast cancer who progress during or within 12 months after adjuvant treatment with trastuzumab and for those who relapse after initially responding to treatment with trastuzumab plus a taxane, with or without pertuzumab. The gene discussed is ERBB2; the disease is breast cancer.